Company intelligence / Profile preview

4basebio

Cambridge, England, United Kingdom4basebio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

4basebio has developed proprietary technologies for the design, manufacture, and supply of high-quality synthetic DNA and mRNA as well as targeted non-viral vectors. Their products are used to accelerate development in advanced therapy medicinal products (ATMPs), including cell and gene therapies and vaccines. The company's approach offers advantages over traditional plasmid DNA or non-targeted lipid nanoparticles by being highly customizable, safer, faster to produce, and plasmid-free.

Modalities: Synthetic DNAmRNA-based drugsNon-viral nanoparticle delivery therapyGene therapy
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on 4basebio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4basebio.

Explore the full profile